Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43843 | 1.00 | MAPT (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL4626004 | 1.00 | MAPT (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL5324038 | 0.90 | USP2 (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL5283079 | 0.90 | USP2 (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL2971633 | 0.88 | GRIA1 (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL2971635 | 0.88 | GRIA1 (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL5282915 | 0.88 | USP2 (0.46) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL23682935 | 0.86 | GRIA1 (0.46) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL13205282 | 0.85 | TSHR (0.42) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL5285947 | 0.84 | USP2 (0.50) | MAPTCYP2C9MEN1KMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | claimed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-12486304-B2 | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof | C-BIOMEX CO., LTD. (KR) | 2025-12-02 | — | — | US | claimed |
| US-12428447-B2 | Peptide-based non-proteinaceous cargo delivery | FELDAN BIO INC. (CA) | 2025-09-30 | — | — | US | claimed |
| US-20250179465-A1 | SITE-SPECIFIC ENCODING OF FLUORINATED PHENYLALANINE RESIDUES IN BACTERIAL AND MAMMALIAN CELLS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-06-05 | — | — | US | claimed |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | claimed |
| CN-117120458-B | Peptide ligands targeting carbonic anhydrase IX, peptide structures comprising the same, and uses thereof | C-比奥麦克斯有限公司 | 2025-04-04 | — | — | CN | claimed |
| EP-4522221-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4479526-A1 | SITE-SPECIFIC ENCODING OF FLUORINATED PHENYLALANINE RESIDUES IN BACTERIAL AND MAMMALIAN CELLS | University of Iowa Research Foundation (US) | 2024-12-25 | — | — | EP | claimed |
| US-20240327464-A1 | PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOF | C-BIOMEX CO., LTD. (KR) | 2024-10-03 | — | — | US | claimed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | claimed |
| US-8435941-B2 | Mini-hepcidin peptides and methods of using thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-07 | — | — | US | claimed |
| EP-1962959-B1 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | claimed |
| EP-1844070-B1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | claimed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | MAPT 4088/4885CYP2C9 4551/4885MEN1 1052/4885 |
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | TMPRSS2, TMPRSS4, F2RL3 | MAPT 3390/4885CYP2C9 3134/4885MEN1 3039/4885 |
| US-12486304-B2 | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof | CA9, CA4, CA12 | MAPT 4177/4885CYP2C9 2581/4885MEN1 1422/4885 |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | MAPT 2599/4885CYP2C9 2575/4885MEN1 358/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | MAPT 3133/4885CYP2C9 4786/4885MEN1 892/4885 |
| US-20240327464-A1 | PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOF | CA9, CA4, CA12 | MAPT 4177/4885CYP2C9 2581/4885MEN1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.